Zealand Pharma major shareholder announcement: Van Herk Investments

Zealand Pharma major shareholder announcement: Van Herk Investments




Zealand Pharma major shareholder announcement: Van Herk Investments

Company announcement – No. 6 / 2024

Zealand Pharma major shareholder announcement: Van Herk Investments

Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 26 January 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:

As of 25 January 2024, Van Herk Investments B.V. (Dutch registration no. 59055057) holds nominally 6.233.183 shares (each share carrying one vote) in Zealand Pharma A/S, corresponding to 9,97% of the total share capital and total voting rights Zealand Pharma A/S.

Van Herk Investments B.V. is 100% owned by Van Herk Investments THI B.V. which is 100% owned by Van Herk Private Equity Investments B.V. (Dutch registration no. 58894543, which is ultimately owned and controlled by Mr. Adrianus van Herk.

Van Herk Management Services B.V. (Dutch registration no. 24377325) controls and exercises the voting rights on behalf of Van Herk Investments B.V., and accordingly, Van Herk Management Services B.V controls and exercises the voting rights on nominally 6.233.183 shares (each share carrying one vote), corresponding to 9,97% of the total share capital and total voting rights in Zealand Pharma A/S.

Van Herk Management Services B.V., is controlled by OGBB A. van Herk B.V. (Dutch registration no. 24160906), which is controlled by A. van Herk Holding B.V. (Dutch registration no. 24160780), which is ultimately controlled by Mr. Adrianus van Herk.

Please see further details in the attached notification forms.

# # #

About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand has a team in the U.S. For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.

Contact:

Adam Lange (Investors)
Investor Relations Officer
Zealand Pharma
alange@zealandpharma.com
 
Anna Krassowska, PhD (Investors and Media)
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
akrassowska@zealandpharma.com

Attachments